Poor
Partially Aligned
Patient Risk:
Medium
Summary
Several grapefruit/statin interaction claims (e.g., grapefruit juice increases atorvastatin exposure via CYP3A4 inhibition; risk increased with higher quantities; counsel on muscle symptoms) are broadly consistent with the supplied label text, but multiple specific assertions about grapefruit oil/handling, exact thresholds (e.g., >1.2 L/day vs >1 liter), and the claim that the 'key concern' is CYP3A4 for atorvastatin are not supported by the provided label excerpts. The response also includes counseling/instruction language not present in the supplied label.
Category Scores
Accurate Statements
Grapefruit juice contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).
Label section 7.2 Grapefruit Juice.
Patients should be advised of risk of myopathy and told to report promptly unexplained muscle pain, tenderness, or weakness; the risk is increased when consuming larger quantities (>1 liter) of grapefruit juice.
Label section 17.1 Muscle Pain.
Atorvastatin can cause myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values >10 times ULN.
Label section 5.1 Skeletal Muscle.
Unsupported Statements
Grapefruit can reduce the effectiveness of some statins.
No supplied label text states that grapefruit reduces statin effectiveness; supplied sections discuss increased atorvastatin concentrations and myopathy risk.
Grapefruit can increase the risk of side effects of some statins.
The supplied label supports increased plasma concentrations of atorvastatin and increased risk of myopathy (via grapefruit juice quantity). It does not broadly support 'side effects of some statins' as phrased.
For atorvastatin (Lipitor), the key concern is grapefruit’s interaction with the CYP3A4 pathway.
The label excerpt supports CYP3A4 inhibition by grapefruit juice (7.2) but does not state this as the 'key concern.'
Grapefruit can raise atorvastatin levels rather than lower its effect.
The supplied label supports increased plasma concentrations of atorvastatin from grapefruit juice. However, the 'rather than lower' framing is not explicitly stated in the supplied label.
Grapefruit is considered a meaningful interaction risk for statins like Lipitor.
The label excerpt supports grapefruit juice interaction for atorvastatin in sections 7.2 and 17.1, but does not provide the broader comparative phrasing 'statins like Lipitor' or the term 'meaningful.'
Grapefruit contains compounds that inhibit enzymes and transporters that normally help metabolize and clear many medications.
Not supported by the supplied excerpts; only CYP3A4 inhibition and increased atorvastatin concentrations are shown.
Inhibition from grapefruit can increase drug exposure in the body.
The label supports increased plasma concentrations of atorvastatin, but the general statement about systemic 'drug exposure in the body' for grapefruit is not explicitly provided.
Grapefruit interaction guidance for statins is typically based on grapefruit’s ability to change atorvastatin blood levels through metabolic pathways.
The supplied label excerpt does not discuss what guidance is 'typically based on' or broader generalities.
Grapefruit juice is the best-studied form of grapefruit-drug interaction.
Not stated in the supplied label excerpts.
Grapefruit oil (essential oil) may have different compound concentrations and dosing patterns than grapefruit juice.
Not addressed in the supplied label.
Grapefruit oil can contain relevant grapefruit compounds.
Not stated in the supplied label.
Unless a grapefruit oil product is clearly shown to be free of interaction components, it is treated as potentially interacting with Lipitor.
Not supported by the supplied label; label section 7.2 and 17.1 address grapefruit juice and quantities.
Grapefruit could affect absorption and metabolism in ways that change how much atorvastatin reaches the bloodstream.
The label excerpt states increased plasma concentrations; it does not describe absorption/metabolism mechanisms beyond 'inhibit CYP 3A4.'
In practice, the well-known grapefruit-statin issue is increased atorvastatin exposure (higher levels), not reduced cholesterol efficacy.
No statement about 'cholesterol efficacy' is included in the supplied excerpts.
Grapefruit products are generally avoided rather than used to 'fine-tune' effects in order to avoid changing how Lipitor works.
Not supported in supplied label excerpts.
Avoid using grapefruit oil while on Lipitor unless a clinician or pharmacist specifically approves it.
No grapefruit oil guidance exists in the supplied label excerpts.
If someone already uses grapefruit oil while taking Lipitor, they should ask a pharmacist whether that product is likely to contain significant grapefruit compounds and whether to switch to a different essential oil.
Not supported; counseling in label excerpts addresses grapefruit juice quantities and reporting muscle symptoms.
Higher atorvastatin exposure can increase the chance of statin-related side effects.
The label supports increased myopathy risk and reports of adverse reactions broadly, but does not state this causal phrasing tied to 'higher exposure' for side effects generally.
Statin-related side effects can include muscle pain or weakness.
Muscle pain/weakness are included in the label as myopathy symptoms, but the phrasing 'statin-related side effects can include' is broader than what is explicitly provided. The label specifically instructs patients to report unexplained muscle pain/tenderness/weakness as myopathy symptoms.
Symptoms suggesting a possible interaction issue include unexplained muscle symptoms, dark urine, or unusual fatigue.
The supplied label excerpts mention muscle pain/tenderness/weakness and rhabdomyolysis with acute renal failure secondary to myoglobinuria, but do not list 'dark urine' or 'unusual fatigue' as interaction symptoms in the grapefruit context.
These symptoms should prompt medical advice, especially soon after starting or increasing grapefruit oil or any grapefruit product.
The label excerpt advises prompt reporting of unexplained muscle pain/tenderness/weakness and discusses monitoring timing for interacting drugs in general, but does not mention grapefruit oil or timing 'soon after' starting/increasing grapefruit oil.
Contradictions
Low
AI Statement
Grapefruit juice consumption threshold is >1.2 liters per day (implied to be the relevant threshold for increased risk).
Label Reference
Label 17.1 Muscle Pain indicates increased risk when consuming larger quantities (>1 liter) of grapefruit juice.
Important Omissions
No mention that label counseling specifically addresses grapefruit juice quantities (>1 liter) in the risk of myopathy, rather than grapefruit oil or essential oils.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The label supports grapefruit juice increasing atorvastatin concentrations and increasing myopathy risk with larger quantities, but the response adds unsupported grapefruit oil/essential oil guidance and symptom lists (e.g., dark urine, unusual fatigue) and specific thresholds that are not consistently aligned with the supplied label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Unsupported grapefruit oil/essential oil guidance and several generalized or rephrased interaction/safety statements not present in the supplied label excerpts; inconsistent grapefruit juice quantity thresholds.
Suggested Improvement
Limit interaction claims to grapefruit juice as stated in the label (7.2) and patient counseling (17.1). Remove grapefruit oil/essential oil-specific instructions unless the supplied FDA label text explicitly covers them. Align quantity thresholds exactly as written in the label excerpt (>1.2 liters/day in 7.2 and >1 liter in 17.1). Keep symptom counseling to the label’s muscle pain/tenderness/weakness reporting language.